BTIG has hired Yun Zhong to the firm’s growing research and strategy division as a publishing analyst on the healthcare equity research team. Zhong’s research coverage will focus on the biotechnology subsector, where he will specialize in gene therapy, genetic medicine, targeted therapy, rare disease and hematology. In his new role, he also joins the firm as a director within the research and strategy division, where he will report to Ryan Serwin, BTIG director of research.
“We are very pleased to welcome Yun to the BTIG Biotechnology Equity Research team,” noted Serwin. “Biotechnology continues to be one of the most active subsectors for clients of our healthcare practice. We believe that Yun’s decade of experience covering biotechnology companies makes him exceedingly qualified to help clients evaluate their investment opportunities in the space.”
Prior to BTIG, Zhong was a biotech equity research analyst at Berenberg Capital Markets.
Zhong joins BTIG’s team of publishing biotechnology analysts including Bert Hazlett, Thomas Shrader, Justin Zelin and Julian Harrison. Biotechnology continues to be a core area of growth for the firm which increasingly offers differentiated and actionable expertise for institutional and corporate clients.